The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels.

Tempus AI could capture a lucrative slice of Moderna and Merck's personalized cancer therapy business, with Personalis at the center of the bet.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。